X-ray imaging of the chest in Switzerland in 1998: a nationwide survey by Aroua,  Abbas et al.
   
 
 
 
 
Serveur Acade´mique Lausannois SERVAL serval.unil.ch
Author Manuscript
Faculty of Biology and Medicine Publication
This paper has been peer-reviewed but does not include the final publisher
proof-corrections or journal pagination.
Published in final edited form as:
Title: Toxicokinetics of captan and folpet biomarkers in orally exposed
volunteers.
Authors: Berthet A, Bouchard M, Danuser B
Journal: Journal of Applied Toxicology
Year: 2012
Issue: 32
Volume: 3
Pages: 194-201
DOI: 10.1002/jat.1653
In the absence of a copyright statement, users should assume that standard copyright protection applies, unless the article contains
an explicit statement to the contrary. In case of doubt, contact the journal publisher to verify the copyright status of an article.
1 
 
 
 
Toxicokinetics of captan and folpet biomarkers in orally exposed volunteers 
 
 
 
Aurélie Berthet,ab Michèle Boucharda* and Brigitta Danuserb 
 
 
 
 
 
a Département de santé environnementale et santé au travail, Chaire d’analyse et de gestion des 
risques toxicologiques and Institut de recherche en santé publique de l’Université de Montréal 
(IRSPUM), Faculté de Médecine, Université de Montréal, C.P. 6128, Succursale Centre-ville, 
Montréal, Québec, Canada, H3C 3J7 
 
b Institute for Work and Health, Rue du Bugnon 21, 1011 Lausanne, Switzerland 
 
 
 
 
 
 
 
 
Correspondence to:  
M. Bouchard, Département de Santé environnementale et santé au travail, Université de 
Montréal, C.P. 6128, Succursale Centre-ville, Montréal, Québec, H3C 3J7, Canada. 
E-mail: michele.bouchard@umontreal.ca 
 Telephone number: (514) 343-6111 ext 1640 
 Fax number: (514) 343-2200 
 
 
 
 
Short title: Oral kinetics of captan and folpet biomarkers 
2 
 
ABSTRACT: The time courses of key biomarkers of exposure to captan and folpet was 
assessed in accessible biological matrices of orally exposed volunteers. Ten volunteers 
ingested 1 mg kg-1 body weight of captan or folpet. Blood samples were withdrawn at fixed 
time periods over the 72 h following ingestion and complete urine voids were collected over 
96 h post-dosing. The tetrahydrophthalimide (THPI) metabolite of captan along with the 
phthalimide (PI) and phthalic acid metabolites of folpet were then quantified in these 
samples. Plasma levels of THPI and PI increased progressively after ingestion, reaching peak 
values ≈10 and 6 h post-dosing, respectively; subsequent elimination phase appeared 
monophasic with a mean elimination half-life (t½) of 15.7 and 31.5 h, respectively. In urine, 
elimination rate time courses of PI and phthalic acid evolved in parallel, with respective t½ of 
27.3 and 27.6 h; relatively faster elimination was found for THPI, with mean t½ of 11.7 h. 
However, phthalic acid was present in urine in 1 000-fold higher amounts than PI. In the 96-
h period post-treatment, on average 25% of folpet dose was excreted in urine as phthalic acid 
as compared to only 0.02% as PI. Corresponding value for THPI was 3.5%. Overall, THPI 
and PI appear as interesting biomarkers of recent exposure, with relatively short half-lives; 
their sensitivity to assess exposure in field studies should be further verified. Although not a 
metabolite specific to folpet, the concomitant use of phthalic acid as a major biomarker of 
exposure to folpet should also be considered. 
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Table of Contents – Short abstract 
 
To determine the kinetics of ring metabolites of captan and folpet in human matrices following an 
oral exposure, volunteers ingested 1 mg kg-1 of these two largely used fungicides. Blood samples 
and complete urine voids were collected at fixed time periods respectively over 72 h and 96 h 
following ingestion. The results show a relatively short half-life for the three studied metabolites 
as well as their sensitivity as biomarkers of exposure to captan and folpet. 
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INTRODUCTION 
 
Captan and folpet are widely used in different crops to treat fungal diseases. Health effects were 
documented mostly from animal toxicity studies (US EPA, 1975, 1999). No direct toxicity was 
reported in humans, except allergic dermatitis, severe eye irritations and irritation of the nose and 
throat (Hayes, 1982; Lisi et al., 1987; ACGIH, 1991; Edwards et al., 1991; Trochimowicz et al., 
1991; Guo et al., 1996; Tomlin, 1997; Costa, 2008; Gordon, 2010). Nonetheless, folpet was 
classified B2, or probable human carcinogen, by the U.S. Environmental Protection Agency (US 
EPA, 1975, 1999), based on an increased incidence of duodenum tumors in mice chronically 
exposed to high doses by gavage. Captan was also found to induce the same type of tumors in mice 
through the same mode of action and was thus initially categorized B2. However, in 2004, the US 
EPA revised the classification of captan and changed it to “not likely” (US EPA, 2004; Gordon, 
2007), given that cancers were observed at doses several orders of magnitude higher than those 
encountered in occupational settings, which promoted proliferation of nascent tumors through 
cytotoxicity and cell hyperplasia.  
 
The US EPA (1975, 1999) has also derived a reference dose (RfD) to prevent chronic effects of 
ingested captan and folpet in the general population. It was respectively established at 0.1 mg kg-1 
of body weight (body wt) for captan (value estimated on the basis of a no-observed adverse effect 
level (NOAEL) of 12.5 mg kg-1 of body wt per day in a three-generation reproduction study in rats 
to which a safety factor of 100 was applied), and 0.16 mg kg-1 body wt per day for folpet (value 
assessed on the basis of a no-observed effect level (NOEL) of 10 mg kg-1 of body wt per day from 
a one-year toxicity study on dogs and a two-years toxicity and carcinogenicity study in rats to 
which a safety factor of 100 was applied) (Larsen, 1996). 
 
With regard to captan and folpet metabolism (Fig. 1 and 2, respectively), it has been fairly well 
documented in in vivo studies in animals usually exposed to the radiolabelled compounds as well 
as in vitro studies, but human data are limited (Gordon, 2010). According to these studies, captan 
is broken down to 1,2,3,6-tetrahydrophthalimide (THPI) and thiophosgene (Wolfe et al., 1976). 
Thiophosgene is an unstable metabolite with a very short half-life that reacts in vivo with thiol 
groups or several functional groups to form thiazolidine-2-thione-4-carboxylic acid (TTCA) 
(Wolfe et al., 1976). THPI and TTCA have been proposed as biomarkers of captan exposure 
(DeBaun et al., 1974; Krieger and Thongsinthusak, 1993). Both these metabolites can be quantified 
in human urine as evidenced by the only published urinary excretion time course study in two 
volunteers exposed to captan by the oral route (Krieger and Thongsinthusak, 1993). However, only 
THPI was repeatedly used as a biomarker in the few cross-sectional biomonitoring studies reported 
among workers exposed to captan (Winterlin et al., 1984; Winterlin et al.,  1986; van Welie et al., 
1991; de Cock et al., 1998; Krieger and Dinoff, 2000; Hines et al., 2008). TTCA may also appear 
as a potential biomarker of captan exposure, but it is not specific to this fungicide and only van 
Welie et al. (1991) quantified it in the urine of exposed workers.  
 
On the other hand, in in vivo experiments in animals and in vitro studies, folpet was shown to be 
first hydrolyzed to phthalimide (PI) and thiophosgene (Gordon et al., 2001; Zainal and Que Hee, 
2003; Canal-Raffin et al., 2008; Gordon, 2010). Thiophosgene forms TTCA in the same way as 
captan, and PI is rapidly hydrolyzed in animals to unstable phthalamic acid, but also to phthalic 
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acid (Gordon, 2010). However, to our knowledge, there are no reported kinetic studies in humans 
for folpet to date. 
 
Overall, there is a lack of detailed knowledge of the toxicokinetics of captan and folpet in humans 
necessary to interpret biomarker data in field studies and to relate biomarker data to health effects. 
Since interspecies differences in the kinetics of chemical substances are likely to occur (Krieger 
and Thongsinthusak, 1993; Poet and McDougal, 2002; Ngo et al., 2010) and given the high doses 
administered in the animal studies on captan and folpet compared to occupational and 
environmental exposure levels, it is difficult to extrapolate a priori animal time course data to 
humans. As mentioned by Finley and Paustenbach (1997) and Woollen (1993), information 
obtained directly in humans will avoid some factors of uncertainty that are present in animal 
studies, and may give indications on the individual variability in metabolism and elimination of the 
studied substances. The aim to this study was thus to determine kinetics of captan and folpet 
metabolites in accessible biological matrices of orally exposed volunteers to help better assess 
biomonitoring data.  
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MATERIALS AND METHODS 
 
Study design 
 
A controlled kinetic time course study in accessible biological matrices of healthy subjects was 
conducted following an acute oral exposure to captan and folpet. Captan and folpet metabolites 
were measured in urine and blood samples collected prior to treatment to obtain pre-test values, 
and then at predetermined time points post-dosing (amounting to a total of 9 samples for plasma 
and 11 samples for urine). 
 
The experimental protocol and consent forms were approved by the Permanent Ethics Committee 
for Clinical Research of the Faculty of Biology and Medicine of the University of Lausanne and 
the Research Ethics Committee of the Faculty of Medicine of the University of Montreal. All the 
participants gave their written consent, and were informed of the risks of participating and their 
right to withdraw from the study at anytime. As suggested by the Ethics Committee who considered 
the study as very restrictive, the participants received a monetary compensation for their time and 
any inconvenience caused. 
 
Subjects studied 
 
Participants were recruited on a voluntary basis among the medical students of the University of 
Lausanne, Switzerland. The volunteers were ten male students aged from 20 to 30 years old, 
weighing 60 to 85 kg and measuring 169 to 184 cm in height. They were healthy, non-smokers and 
did not take medication or drugs. They underwent a medical examination by an occupational 
physician prior to enrolment. They had never been exposed to captan or folpet, except perhaps 
through their diet. During the study period and the two-days prior to dosing, they were asked not 
to eat fruits and vegetables in order to limit ingestion of contaminated food. They were also 
requested to avoid consumption of alcohol during this period, since it is known to affect the 
metabolism of some chemical compounds. 
 
Dosing and sampling 
 
The experimental dosing and sampling was conducted at the Institute for Work and Health of 
Lausanne, Switzerland. The morning of study onset, each participant was asked to collect his 
complete first morning urine void, to obtain pre-test values; they then spent the first day of the 
study in a room at the Institute for dosing and the first 12-h sampling. On the following 3-day 
sampling period, participants visited the Institute for their daily morning blood sampling and 
handing-in urine collections. 
 
The volunteers ingested a dose of captan or folpet equivalent to 1 mg kg-1 body wt (n = 5 per 
group). Fungicides used to prepare the exposure dose of volunteers were Captan PESTANAL® 
(assay (HPLC) area 99.1 to 99.4%) and Folpet PESTANAL® (assay (HPLC) area 99.5 to 99.9%). 
Both were purchased from Fluka – Sigma-Aldrich (Buchs, St Gallen, Switzerland). The single dose 
was weighted in a labelled plastic cup and adjusted to the weight of each volunteer. The fungicide 
dose was mixed with 25 ml of orange juice and administered to the participants. The cup used for 
dosing was then rinsed with another 25 ml of orange juice and also administered to the participants. 
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Complete micturitions were then collected at pre-determined times over the 96–h period post-
dosing, that is at around 0, 3, 6, 9, 12, 24, 36, 48, 60, 72, 84 and 96 h post-dosing. Each timed-void 
was collected in separate polypropylene Nalgene® bottles of 1 l. To assist participants, they 
received a schedule specifying the date and the required time of urine collection. They then only 
had to complete the sheet with the actual time of collection and to indicate whether or not there 
were any urine losses. They also had to identify their plastic bottles with distinct pre-printed labels 
indicating the code, and mark on them the date and time of urine collection.  
 
Once collected, urine samples were kept in the refrigerator prior to measurement of total urine 
volume per void. To allow repeated analysis while avoiding possible degradation due to freezing 
and defreezing of samples, each urine collection then was aliquoted in 4 labelled tubes of 15 ml 
and one bottle of 120 ml before storage at -20°C until analysis of captan or folpet metabolites. 
 
Blood samples of 15 ml were also collected at specific times, that is at t = 0, 2, 4, 6, 8, 10, 24, 48 
and 72 h post-dosing. To facilitate collection, a catheter was installed by a nurse prior to dosing 
along with a drip system of physiological saline the first day of sampling. Blood was withdrawn 
by the nurse into vacutainers pre-labelled with a code, the date and time of sampling. Immediately 
after collection, blood samples were centrifuged to precipitate red blood cells and isolate the 
plasma. The plasma samples were then split into 3 labelled aliquots and stored at -20°C until 
analysis of captan and folpet metabolites. 
 
During the study period, volunteers were also asked to fill a questionnaire to document personal 
information (weight, height), life habits (i.e. physical activities, smoking), medication intake 
(including ibuprofen), alcohol consumption during the 3 days prior to treatment, consumption of 
fruits, vegetables and cereals during the 4 days prior to treatment and possible dosing-related 
symptoms. 
 
Chemicals and reagents 
 
Reference standards (>99% purity) were obtained from Sigma-Aldrich (Buchs, St Gallen, 
Switzerland), except for deuterated cis-1,2,3,6-tetrahydrophthalimide (THPI-d) (99% purity), 
which was purchased from Cambridge Isotope Laboratories Inc. (Andover, MA, USA). HPLC 
grade acetonitrile, methanol, ethyl acetate and dichloromethane were also obtained from Sigma-
Aldrich (Buchs, St Gallen, Switzerland), along with N,O-bis(trimethylsilyl)trifluoroacetamide 
(BSTFA), the reagent used to derivatize the phthalic acid molecule. HCl and ammonium sulphate 
were purchased from Merck (Zug, Switzerland). Water was purified using a TKA GenPure water 
treatment system obtained from TKA Wasseraufbereitungssysteme GmbH (Niederelbert, 
Germany).  
 
Analysis of THPI and PI in plasma and urine 
 
A liquid chromatography - atmospheric pressure chemical ionization-tandem mass spectrometry 
(LC/APCI-MS/MS) method was developed to analyze THPI and PI in urine and plasma and is 
described elsewhere (Berthet et al., 2011a). Briefly, THPI and PI were isolated by adding 125 µl 
of THPI-d internal standard (1.59 µmol l-1) in 3 ml of urine or 2 ml of plasma, conditioning the 
Oasis® solid phase extraction cartridge (Waters, Montreux, Switzerland) with 8 ml of 
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dichloromethane followed by 8 ml of methanol and 12 ml of water, and lastly by loading aliquots 
on SPE cartridges (in the case of plasma, following a denaturation of proteins). The analytes were 
then eluted from the column with 4 ml of dichloromethane. The solvent was evaporated to dryness 
under a gentle nitrogen flow at 40°C. The residues were resuspended in 500 µl of methanol and 
analyzed using a Varian Model 212-LC Binary Gradient LC system (Les Ulis, France) connected 
to a Prostar model 410 autosampler (Varian, Les Ulis, France) and coupled to a Model 1200 L 
quadrupole MS (Varian, Les Ulis, France) operating in APCI mode. The APCI interface was 
operated in negative ion mode. The compounds were separated using a C18 Zorbax Eclipse Plus 
column (4.6 x 150 mm, 3.5 µm) from Agilent (Morges, Switzerland). The mobile phase consisted 
of: eluent A composed of 90 % water and 10% acetonitrile (v/v), and eluent B of 10% water and 
90% acetonitrile (v/v). For THPI analysis, 10 µl of the sample were injected and elution was 
performed in 26 min at a flow rate of 0.8 ml min-1 using a solvent gradient starting at 90% eluent 
A for 3 min, followed by a linear gradient to 5% eluent A from 3 to 10 min, maintained at 5% 
eluent A from 10 to 13 min before running to initial conditions of 90% eluent A in 1 min for a 12-
min re-equilibration of the column prior to subsequent injection. As for PI analysis, 10 µl of the 
sample were also injected and elution was performed in 33 min at a flow rate of 0.8 ml min-1 using 
an isocratic mode at 90% eluent A for 15 min and then ramping to 5% eluent A in 30 sec for a 4 
min clean up at 5% eluent A prior to returning to initial conditions in 1 min to allow 12 min re-
equilibration of the column. The fragments analyzed were m/z 149.4/95.6 for THPI with a collision 
energy (CE) of 19.5 V, m/z 156.1/95.6 for the internal standard THPI-d (CE of 22.5 V) and m/z 
145.8 for PI (no fragmentation). The analytical limit of detection for THPI was 3.82 nmol l-1 of 
urine and 9.76 nmol l-1 of plasma and, for PI, 7.72 nmol l-1 of urine and 14.8 nmol l-1 of plasma. 
The quantification of THPI or PI was obtained from standard calibration curves prepared in urine 
or plasma adjusted by the THPI-d internal standard peak area. 
 
Analysis of phthalic acid in urine 
 
A gas chromatography mass spectrometry (GC-MS) method was developed for the analysis of 
phthalic acid in urine, as previously described (Berthet et al., 2011b). In short, urine samples were 
subjected to an acid hydrolysis prior to liquid-liquid extraction with ethyl acetate and derivatization 
with N,O-bis(trimethylsilyl)trifluoroacetamide (BSTFA). Analysis was then performed using an 
Agilent Mass Selective Detector (MSD) G1098A (Agilent Technologies Inc, Waldbronn, 
Germany) coupled with a HP 5973 mass spectrometer (Agilent Technologies Inc, Waldbronn, 
Germany). Separation of the analytes was performed using a 60 m CP-SIL 8 CB column (1 µm 
film thickness, 250 µm I.D.) (Varian, Les Ulis, France). The initial column temperature was 200°C 
for 3 min, then it was increased to 260°C at 30°C min-1, held for 11 min, and finally increased to 
280°C at 35°C min-1 and held for 4 min. For the analysis, 2 µl were injected using a 5 ml min-1 
split. The ions monitored were trimethylsilyl phthalic acid (TMS phthalic acid) with m/z 295 and 
the internal standard TMS methylhippuric acid with m/z 220. The quantification was obtained from 
standard calibration curves of phthalic acid prepared in urine and adjusted by the methylhippuric 
acid internal standard peak area. The analytical limit of detection was 60.2 nmol l-1 urine. 
 
 
Calculations 
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The molar fraction of captan or folpet administered dose recovered in urine as THPI, PI or phthalic 
acid was calculated from the following equation: 
⎣
⎢
⎢
⎡ �𝑄𝑄𝑢𝑢𝑢𝑢𝑢𝑢𝑢𝑢𝑢𝑢𝑢𝑢𝑢𝑢 𝑚𝑚𝑚𝑚𝑚𝑚𝑢𝑢𝑚𝑚𝑚𝑚𝑚𝑚𝑢𝑢𝑚𝑚𝑚𝑚  𝑀𝑀𝑀𝑀𝑚𝑚𝑚𝑚𝑚𝑚𝑢𝑢𝑚𝑚𝑚𝑚𝑚𝑚𝑢𝑢𝑚𝑚𝑚𝑚 �
�
𝐷𝐷𝐷𝐷𝐷𝐷𝐷𝐷𝑝𝑝𝑢𝑢𝑢𝑢𝑚𝑚𝑢𝑢𝑚𝑚 𝑐𝑐𝑚𝑚𝑚𝑚𝑝𝑝𝑚𝑚𝑢𝑢𝑢𝑢𝑐𝑐 
𝑀𝑀𝑀𝑀𝑝𝑝𝑢𝑢𝑢𝑢𝑚𝑚𝑢𝑢𝑚𝑚 𝑐𝑐𝑚𝑚𝑚𝑚𝑝𝑝𝑚𝑚𝑢𝑢𝑢𝑢𝑐𝑐 �⎦⎥
⎥
⎤  × 100 
 
where Qurinary metabolite corresponds to total amounts of THPI, PI or phthalic acid in urine over the 
96-h urine collection period (mg), MWparent compound is the molecular weight of captan or folpet, 
MWmetabolite is the molecular weight of THPI, PI or phthalic acid and Doseparent compound is the orally 
administered dose of captan or folpet (mg). 
 
Toxicokinetic analysis 
 
To determine elimination rate constants of THPI and PI in plasma and in urine, we considered that, 
following peak levels, elimination was monophasic and a first-order reaction. The elimination rate 
constant (k) was thus calculated from the slope of the linear terminal phase of the plasma or urine 
time profile (Hayes, 2008). The apparent elimination half-life (t1/2) was then defined using the 
equation t1/2 = 0.693 k -1 (Hayes, 2008). All calculations were performed using MS Excel® 2007 
software. 
 
From plasma concentration (C) - time profile, we also calculated the area under the concentration-
time curve (AUC), the area under the first moment of concentration-time curve (AUMC), the mean 
residence time (MRT), the plasma clearance (CL) and the apparent volume of distribution (Vd). 
Equations used to calculate these parameters are: 
𝐴𝐴𝐴𝐴𝐴𝐴 = 12�(𝑡𝑡𝑢𝑢
∀𝑢𝑢
− 𝑡𝑡𝑢𝑢+1)[𝐴𝐴(𝑡𝑡𝑢𝑢) + 𝐴𝐴(𝑡𝑡𝑢𝑢+1)] 
𝐴𝐴𝐴𝐴𝑀𝑀𝐴𝐴 = 12�(𝑡𝑡𝑢𝑢
∀𝑢𝑢
− 𝑡𝑡𝑢𝑢+1)[𝑡𝑡𝑢𝑢𝐴𝐴(𝑡𝑡𝑢𝑢) + 𝑡𝑡𝑢𝑢+1𝐴𝐴(𝑡𝑡𝑢𝑢+1)] 
𝑀𝑀𝑀𝑀𝑀𝑀 =  𝐴𝐴𝐴𝐴𝑀𝑀𝐴𝐴
𝐴𝐴𝐴𝐴𝐴𝐴
 
𝐴𝐴𝐶𝐶 =  𝐴𝐴𝐴𝐴𝐷𝐷𝐷𝐷𝐴𝐴𝐴𝐴𝐷𝐷𝐴𝐴 𝐴𝐴𝐷𝐷𝐷𝐷𝐷𝐷
𝐴𝐴𝐴𝐴𝐴𝐴   
𝑉𝑉𝐴𝐴 =  𝐶𝐶𝐶𝐶
𝑘𝑘
   where k is the overall elimination rate from blood 
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RESULTS 
 
Time courses of THPI and PI in plasma 
 
The time courses of THPI and PI in plasma of volunteers over the 72-h period following ingestion 
of captan or folpet (1 mg kg-1 body wt) are presented in Fig. 3. In control samples taken prior to 
captan or folpet ingestion (t0), concentrations of THPI were below the analytical limit of detection 
and those of PI were very low, in the order of 9.3 nmol l-1. Following ingestion, plasma levels of 
THPI and PI increased progressively with peak levels of THPI being observed on average at time 
10 h post-dosing as compared to 6 h post-dosing for PI. Subsequently, elimination phase of THPI 
and PI from plasma appeared monophasic (6-10 h to 72-h post-dosing) with a mean apparent 
elimination half-life of 15.7 and 31.5 h, respectively (Table 1). Table 2 presents the toxicokinetic 
parameters calculated from the THPI and PI time profiles in plasma and shows that THPI had a 
greater bioavailability and faster clearance rate than PI. As also shown in Table 2, PI metabolite in 
plasma represented only a small fraction of folpet dose. Nonetheless, mean residence time (MRT) 
of both THPI and PI was similar and in the order of one day, which is relatively short compared to 
other chemical compounds. THPI and PI also had similar relatively small apparent volume of 
distribution (Vd). 
 
Time courses of THPI, PI and phthalic acid in urine 
 
The time courses of THPI, PI and phthalic acid excretion rate in the urine of volunteers over a 96-
h period following ingestion of 1 mg kg-1 body wt of captan or folpet are presented in Fig. 4. Peak 
levels were observed on average 9 h post-dosing for THPI, and between 3 and 12 h for PI and 
phthalic acid. Following peak excretion, elimination rate time courses evolved in parallel for PI 
and phthalic acid and was relatively slower than that of THPI, with mean apparent elimination half-
lives calculated for the 24- to 96-h period post-dosing being 27.3, 27.6 and 11.7 h, respectively. 
Although the time courses of PI and phthalic acid was similar, phthalic acid was present in urine 
in 1 000-fold higher amounts than PI as shown in Fig. 4, and in Fig. 5 depicting the cumulative 
urinary excretion time courses of these metabolites. From the cumulative urinary excretion of PI 
and phthalic acid over the 96-h collection period post-dosing, it was calculated that 25% of the 
ingested dose of folpet was excreted in urine as phthalic acid as compared to only 0.02% as PI. 
Corresponding value for THPI was 3.5%.  
 
Figure 6 shows that the time course of THPI in urine obtained in our study is similar to that obtained 
by Krieger and Thongsinthusak (1993) in volunteers orally exposed to the same dose of captan. In 
the current study, cumulative urinary excretion of THPI over the 96-h collection period post-
treatment represented 3.5% of the administered dose, which is compatible with the value of 2.2% 
over the 72-h collection period in the study of Krieger and Thongsinthusak (1993). Similar to 
Krieger and Thongsinthusak (1993), elimination of THPI in urine was almost complete 96 h post-
dosing. 
 
Comparison of plasma and urinary time courses of THPI and PI 
 
As expected for both THPI and PI, comparison of the plasma and urinary rate time courses in the 
studied volunteers (Fig. 3 and 4) shows that profiles evolved in parallel in the 10- to 72-h period 
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post-dosing. However, for both THPI and PI, plasma levels (nmol) were about 50-fold higher than 
urinary excretion rates (nmol h-1), indicating that the transfer rate of THPI and PI from plasma to 
urine was approximately 0.02 per hour, corresponding to a half-life of ≈30 h. 
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DISCUSSION 
 
This study allowed a better understanding of the kinetics of key biomarkers of exposure to captan 
and folpet. It provided novel human data on the kinetics of THPI in plasma, and PI and phthalic 
acid in plasma and urine, while confirming THPI urinary data of Krieger and Thongsinthusak 
(1993). Interestingly, several similarities were observed with available toxicokinetics of total 
radioactivity measured in rats orally exposed to labelled captan or folpet. 
 
Results of the current study showed that the metabolite of captan, THPI, and the metabolites of 
folpet, PI and phthalic acid, had a rapid kinetics in humans after a single oral dose of 1 mg kg-1 
body wt, since these metabolites were almost completely excreted over a 96-h period post-
treatment. Peak levels in plasma were observed on average 10 h post-ingestion for THPI and 6 h 
post-dosing for PI while elimination half-life of THPI from plasma was in the order ≈15 h as 
compared to ≈30 h for PI.  
 
Results of the current study also show negligible storage in tissues. Indeed, from the plasma time 
course, similar relatively small volume of distribution (Vd) were calculated for THPI and PI, 
suggesting these compounds remain mainly in the circulation and have limited distribution in body 
tissues, implying a low storage of these compounds in tissue. This is in line with animal studies 
showing negligible accumulation of THPI (Piccirillo, 2001) or phthalimide moiety (Couch et al., 
1977; Ackermann et al., 1978) in tissues following oral or intraperitoneal administration of labelled 
captan or folpet. 
 
Furthermore, although the time courses of PI and phthalic acid evolved in parallel, PI metabolite 
in plasma represented only a small fraction of folpet dose and only 0.03% of the folpet dose was 
recovered in urine as PI while 25% of the folpet dose was excreted in urine as phthalic acid over 
the 96-h period post-dosing. This is consistent with a rapid site-of-entry biotransformation of PI 
into phthalimic acid and phthalic acid once formed (Ackermann et al., 1978; Canal-Raffin et al., 
2008), thus limiting the amounts of PI available for absorption in blood. It also shows that the acids 
formed in the GI following oral exposure are effectively absorbed. 
 
Results obtained in the current study on the fraction of ingested dose recovered in urine as folpet 
metabolites is in accordance with mass-balance studies conducted in animals exposed to labelled 
folpet. When PI was orally administered to rats, about 80% of the administered dose was 
metabolized and excreted in urine as phthalamic acid while 7% was found as phthalic acid, and 
less than 1% of the dose was recovered as PI in urine (Chasseaud et al., 1974). Phthalamic acid 
also represented the main metabolite (i.e. 80%) when labelled 14C-folpet was orally administered 
to rats (Chasseaud, 1980). They however reported that this metabolite was unstable in urine.   
 
In comparison with the folpet metabolites assessed in our study, on average 3.5% of the 
administered oral dose of captan was excreted as THPI in the urine of volunteers over the 96-h 
collection period. As shown in Fig. 6, these findings are similar to those obtained by Krieger and 
Thongsinthusak (1993) where 2-3% of the same orally administered dose of captan was recovered 
as THPI in the urine of a human volunteer over the 72-h period post-dosing. These human values 
are in the same range as those reported in a unique published animal study on the excretion of 
specific metabolites following non-labelled administration (van Welie et al., 1991). Namely, van 
12 
 
Welie et al. (1991) reported that on average 0.7 to 5.4% of a single oral dose of 400, 815 or 1250 
mg kg-1 of captan in Wistar rats were recovered in urine as THPI over the 0-24 h period post-dosing 
as compared to 2.8 to 9.1% over the 0-48 h period post-dosing, with lowest percentages observed 
at the highest dose. When non-labelled THPI itself was administered orally to rats, van Welie et al. 
(1991) also observed that on average only 4% of dose was recovered as THPI in urine over the 0-
48 h period post-dosing. 
 
It is to be noted that although a small percentage of orally administered captan in volunteers and 
rats was observed as THPI in urine, following oral administration of ring-labelled captan in 
animals, the majority of the radioactivity was recovered in urine (75 to 85% of administered dose) 
over a 24-h to 96-h period post-dosing, while only 7 to 12% of dose were excreted in feces over 
the same period of time. More precisely, Lappin and Havell (1990) reported that 81% of an oral 
dose of 10 mg kg-1 of 14C-ring-captan were recovered in urine as labelled equivalents as compared 
to 8-9% in feces over a 96-h period post-dosing, and 97% of the dose were eliminated at this time. 
Similarly, Trivedi (1990) reported that, following an oral administration of 10 mg kg-1 of 14C-ring-
labelled captan, 75% of the administered dose were excreted in urine as 14C-equivalents and 6.5% 
in feces over the 24-h period post-dosing.  
 
Similarly to captan, following oral or intraperitonal administration of ring-labelled folpet, between 
90 and 100% of the administered dose were excreted in the urine of rats over a 24-h period post-
dosing. This is based on the studies of Wood et al. (1991) showing that 92% of an orally 
administered dose of 10 mg kg-1 of 14C-labelled folpet in rats were recovered in urine as 14C 
equivalents as compared to 6% in feces, and on the study of Couch et al. (1977) indicating that 
virtually 100% of an intraperitoneal dose of 6 mg kg-1 of 14C-folpet were recovered in urine as 14C 
equivalents and 1.7% in feces over the 24-h period post-dosing. 
 
This confirms that, in humans as observed in animals (Lappin and Havell, 1990; van Welie et al., 
1991), studied PI and THPI metabolites are not the main metabolites of captan and folpet following 
oral exposure. As shown by our results and reported by van Welie et al. (1991), other metabolites 
of captan might be more representative than THPI, although the analytical method developed by 
our team for this metabolite was specific, accurate and sensitive. Following an oral administration 
of 10 or 500 mg kg-1 of 14C-ring-labelled captan in Sprague-Dawley rats, Lappin and Havell (1990) 
identified six metabolites other than THPI in urine: 3-hydroxy-4,5-cyclohexene-1,2-dicarboximide 
(3-OH-THPI) (representing 42% of total urinary metabolites), 5-hydroxy-3,4-cyclohexene-1,2-
dicarboximide (5-OH-THPI) (6%), 6-hydroxy-1-amido-2-carboxy-4,5-cyclohexene (3-OH-THPI-
amic acid) (13%), 1-amido-2-carboxy-4,5-cyclohexene (THPAM) (7%), 4,5-dihydroxy-1,2-
dicarboximide (4,5-diOH-THPI) (6%), and 4,5-epoxy-1,2-dicarboximide (THPI-epoxide) (5%), 
and two unidentified metabolites accounting for 4 and 2% of total urinary metabolites. 
 
Overall, in a perspective of biomonitoring of exposure, THPI and PI appear as interesting 
biomarkers of recent exposure given that they are metabolites specific to captan and folpet, 
respectively, with relatively short half-lives. However, they represent only a small percentage of 
the orally administered dose in our study, such that their sensitivity as biomarkers of exposure in 
workers and even more in the general population remains to be more extensively verified. Other 
metabolites of captan and folpet appear quantitatively more important in human urine than THPI 
or PI. The most important urinary metabolite of captan in rats was found to be 3-OH-THPI (Lappin 
and Havell, 1990); it would be interesting to quantify this metabolite in human urine since the 
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current study indicates that the metabolism and excretion of captan metabolites may be similar in 
rats and humans. Furthermore, this human study in line with the rat studies of Chasseaud et al. 
(1974, 1980) showed that phthalamic or phthalic acid appear as quantitatively more important 
biomarkers than PI while urinary excretion time courses are similar for phthalic acid and PI. 
Nonetheless, phthalic acid is not a metabolite specific to folpet; it is also a derivative of phthalates, 
which are ubiquitous molecules in our environment (Blount et al., 2000; Silva et al., 2007). Given 
these considerations, perhaps the best biomonitoring strategy, to assess occupational or 
environmental exposure, would be to measure multiple metabolites of captan or folpet and to 
perform repeated measurements in time. 
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Table 1. First-order apparent elimination half-lives of THPI and PI in human plasma and of 
THPI, PI and phthalic acid in human urine following ingestion of 1 mg kg-1 of captan or folpet 
 
 
Metabolites Matrices 
Mean first-order 
elimination half-life 
(h)a 
(n=5) 
Coefficient of 
determination 
(R2) 
THPI Plasma 15.7 0.99 
 Urine 11.7 0.98 
PI Plasma 31.5 0.84 
 Urine 27.3 0.86 
Phthalic acid Urine 27.6 0.82 
 
a The elimination half-life (t1/2) was calculated using the equation t1/2 = 0.693 k-1, where k is the 
elimination rate constant obtained from the slope of the linear terminal phase of the plasma profile 
(10- to 72-h period) or urine excretion rate time course (24- to 96-h period) for each metabolite 
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Table 2. Toxicokinetic parameters for THPI and PI in plasma of volunteers following 
ingestion of 1 mg kg-1 of captan or folpet 
 
 
Model parameters 
 
First order toxicokinetic values 
THPI PI 
Mean SD Mean SD 
 (n=5) (n=5) 
AUC [(nmol x h l-1) kg-1] 1 652 289 13.4 3.3 
AUMC [(nmol x h2 l-1) kg-1] 40 647 13 533 397 117 
MRT (h) 23.9 4.0 29.4 2.2 
CL (l h-1) 0.18 0.03 0.09 0.02 
Vd (l) 3.4 0.6 4.3 1.1 
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Captions to figures 
 
 
Figure 1. Captan metabolism according to in vivo studies in animals administered 14C- or 15S- 
radiolabelled doses (Lappin and Havell, 1990; Krieger and Thongsinthusak, 1993) 
 
Figure 2. Folpet metabolism according to in vivo studies in animals and in vitro studies 
(Ackermann et al., 1978; Wood et al., 1991; US EPA, 1999; Canal-Raffin et al., 2008; Gordon, 
2010) 
 
Figure 3. Time courses of THPI and PI in plasma of volunteers (expressed as nmol) over a 
72-h period following ingestion of 1 mg kg-1 of captan or folpet. Each point represents mean and 
vertical bars are standard deviations (n = 5). 
 
Figure 4. Time courses of THPI, PI and phthalic acid excretion rate in urine (expressed as 
nmol/h) of volunteers over 96-h period following ingestion of 1 mg kg-1 of captan or folpet. Each 
point represents mean and vertical bars are standard deviations (n = 5). 
 
Figure 5. Time courses of THPI, PI and phthalic acid cumulative excretion in urine 
(expressed as nmol) of volunteers over a 96-h period following ingestion of 1 mg kg-1 of captan or 
folpet. Each point represents mean and vertical bars are standard deviations (n=5). 
 
Figure 6. Comparison of the time course of THPI urinary excretion rate (expressed as a % 
dose/h) in volunteers of the present study with that obtained by Krieger and Thongsinthusak 
(1993) following ingestion of 1 mg kg-1 of captan. Each point represents mean and vertical bars 
are standard deviations (n = 5). 
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Supplemental table 
 
Average levels of THPI, PI and phthalic acid quantified in plasma and in urine at different points 
time in volunteers orally exposed to 1 mg kg-1 of captan or folpet. 
 
 Concentrations (nmol ml-1)a 
Time 
(h)b 
THPIc 
(mean ± SD) 
PId 
(mean ± SD) 
Phthalic acide 
(mean ± SD) 
Plasma Urine Plasma Urine Urine 
0 0.004 ± 0.01 0 0.009 ± 0.004 0.005 ± 0.003 2.96 ± 1.65 
2 1.14 ± 0.29  0.021 ± 0.012   
4 1.76 ± 0.19  0.029 ± 0.020   
3  0.69 ± 0.27  0.020 ± 0.018 16.06 ± 5.09 
6 2.21 ± 0.38 1.41 ± 0.24 0.027 ± 0.007 0.011 ± 0.007 17.27 ± 3.40 
8 2.51 ± 0.52  0.019 ± 0.006   
9  1.70 ± 0.37  0.007 ± 0.005 21.42 ± 11.0 
10 2.77 ± 0.34  0.016 ± 0.005   
12  2.06 ± 0.59  0.023 ± 0.033 15.82 ± 6.42 
24 2.62 ± 0.47 1.89 ± 0.41 0.013 ± 0.005 0.019 ± 0.008 13.17 ± 3.79 
36  1.36 ± 0.31  0.011 ± 0.004 13.69 ±6.37 
48 1.07 ± 0.39 0.94 ± 0.30 0.010 ± 0.003 0.018 ± 0.013 6.51 ± 3.15 
60  0.54 ± 0.24  0.007 ± 0.002 8.67 ± 8.81 
72 0.31 ± 0.17 0.34 ± 0.18 0.008 ± 0.003 0.007 ± 0.003 6.18 ± 2.41 
96  0.13 ± 0.07  0.005 ± 0.003 5.74 ± 4.62 
a Urinary concentrations observed following sample processing as described in Materials and 
Methods. 
b Fixed time periods (expressed in hour) of urine and blood collections following fungicide 
ingestion. 
c Metabolite of captan. 
d Metabolite of folpet. 
e Metabolite of folpet. 
 
 
 
 
